Safety and efficacy of the structured onboarding steps and initiation protocol for MiniMed™ 780G system among an Egyptian cohort of young people living with type 1 diabetes
Author:
Elhenawy Yasmine I.1ORCID, Shaarawy Mohamed A.2, Selim Esraa M.3
Affiliation:
1. Pediatric and Adolescent Diabetes Unit (PADU), Department of Pediatrics, Faculty of Medicine , Ain Shams University , Cairo , Egypt 2. Regional Pump Consultant , Cairo , Egypt 3. Diabetes Educator and Certified Pump Educator , Cairo , Egypt
Abstract
Abstract
Objectives
The aim of the current study was to evaluate the safety and efficacy of initiation protocol for MiniMed ™ 780G system among an Egyptian cohort of young people living with type 1 diabetes (T1D).
Methods
A prospective single-arm study including 72 participants with T1D. Five days of structured education and training were provided to all users and continuous glucose monitoring (CGM) was initiated on the first day of the training. Users initiated the pump initially in manual mode, with suspend before low feature, for 3 days before shifting to Auto Mode.
Results
The mean HbA1c decreased from 8.72 ± 2.01 % to 6.7 ± 0.4 % (p<0.01). Time in range (70–180 mg/dL) substantially improved from 55.24 % ± 10.35 to 81.7 % ± 5.12 % after spending 84 days in auto mode (p<0.001) with 2.03 % of the time spent below 70 mg/dL. Regarding AHCL compatibility, users spent at least 90 % of time in auto mode.
Conclusions
Young people with T1D successfully initiated the AHCL system, using a tailored structured on-boarding protocol. Structured stepwise initiation protocol and onboarding steps are important prerequisite for participants’ adherence and engagement with the system. Patient education together with optimized pump settings are important predictors of glycemic outcomes.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference22 articles.
1. Miller, KM, Foster, NC, Beck, RW, Bergenstal, RM, DuBose, SN, DiMeglio, LA, et al.. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care 2015;38:971–8. https://doi.org/10.2337/dc15-0078. 2. Tauschmann, M, Thabit, H, Bally, L, Allen, JM, Hartnell, S, Wilinska, ME, et al.. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 2018;392:1321–9. https://doi.org/10.1016/S0140-6736(18)31947-0. 3. Ly, TT, Nicholas, JA, Retterath, A, Lim, EM, Davis, EA, Jones, TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310:1240–7. https://doi.org/10.1001/jama.2013.277818. 4. Bergenstal, RM, Klonoff, DC, Garg, SK, Bode, BW, Meredith, M, Slover, RH, et al.. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224–32. https://doi.org/10.1056/NEJMoa1303576. 5. Petrovski, G, Al Khalaf, F, Campbell, J, Day, E, Almajaly, D, Hussain, K, et al.. Glycemic outcomes of advanced hybrid closed loop system in children and adolescents with type 1 diabetes, previously treated with multiple daily injections (MiniMed 780G system in T1D individuals, previously treated with MDI). BMC Endocr Disord 2022;22:80. https://doi.org/10.1186/s12902-022-00996-7.
|
|